Results 81 to 90 of about 6,340 (200)

An Integrated Network Biology and Molecular Dynamics Approach Identifies CD44 as a Promising Therapeutic Target in Multiple Sclerosis

Pharmaceuticals
Background: Multiple sclerosis (MS) is a neuroinflammatory disease characterized by autoimmune-driven inflammation in the central nervous system that damages axons and destroys myelin. It is difficult to diagnose multiple sclerosis due to its complexity,
Mohammad Abdullah Aljasir
doaj   +1 more source

Epidemiology, Risk Factors and Pathophysiology of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease: An Update

JCC Plus, Volume 1, Issue 3, May 2026.
ABSTRACT Background and Aims Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) represent a unique clinical syndrome affecting up to 80% of PSC patients, characterised by distinct epidemiological patterns, pathophysiological mechanisms and clinical outcomes that differ substantially from either condition occurring independently ...
Luisa Bertin, Paul Henderson, Richard Pollok, Natália Queiroz, Luca Fabris, Edoardo Vincenzo Savarino, Iago Rodríguez‐Lago, Brigida Barberio   +7 more
wiley   +1 more source

Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. [PDF]

, 2019
Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous and complex disease that is imprecisely diagnosed by liver biopsy. NAFLD covers a spectrum that ranges from simple steatosis, nonalcoholic steatohepatitis (NASH) with varying degrees of fibrosis,
Alonso, Cristina, Lu, Shelly C, Mato, José M, Noureddin, Mazen   +3 more
core  

Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis [PDF]

, 2019
BACKGROUND: The last decade has seen a rapid growth in the number of clinical trials enrolling patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH).
Adams, Aithal, Andrade, Angulo, Armstrong, Arroyo, Athyros, Avigan, Banderas, Bays, Belfort, Bjornsson, Caldwell, Chalasani, Chalasani, Chalasani, Chalasani, Chalasani, Chalasani, Chalasani, Cusi, De Denus, De Santis, Dutta, Eijgenraam, Ekstedt, Ekstedt, European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), Fontana, Friedman, Friedman, Giannini, Guha, Hayashi, Hoofnagle, Hyysalo, Im, Jalan, Kaplan, Kleiner, Kleiner, Kolwankar, Kowdley, Kullak-Ublick, Kwok, LaBrecque, Lavine, Lewis, Lewis, Liddle, Lo Re, Loomba, Maurice, McPherson, Moylan, Mudaliar, Neuschwander-Tetri, Panteghini, Pantsari, Patel, Patel, Pfeffer, Ratziu, Ratziu, Regev, Reid, Robles-Diaz, Rockstroh, Russo, Sanyal, Sanyal, Sanyal, Scorletti, Senior, Siddiqui, Stefan, Tarantino, Temple, Valenti, Verna, Vilar-Gomez, Vuppalanchi, Vuppalanchi, Vuppalanchi, Watkins, Weltman, Wong, Younossi, Younossi, Zelber-Sagi, Zhou, Zimmerman   +91 more
core   +1 more source

Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 5, May 2026.
We systematically summarized the etiologies, diagnostic approaches, and pathogenic mechanisms of liver fibrosis. Also, the therapeutic interventions for liver fibrosis were systematically classified into two main categories: etiological treatment and mechanism‐based antifibrotic therapies.
Jiaorong Qu, Wenqing Qin, Minghang Dong, Zhi Ma, Si Li, Runping Liu, Ranyun Chen, Changmeng Li, Xiaojiaoyang Li   +8 more
wiley   +1 more source

Obeticholic-acid [PDF]

Reactions Weekly, 2021
  +4 more sources

Population Pharmacokinetics and Pharmacokinetics‐Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Elafibranor 80 mg/day is approved for second‐line primary biliary cholangitis (PBC) treatment. We present pharmacokinetic (PK) analyses of elafibranor and its metabolite, GFT1007, and pharmacokinetic‐pharmacodynamic (PKPD) analyses describing the relationship between their exposure and responses in alkaline phosphatase (ALP) and total ...
Qing Xi Ooi, Karl Brendel, Stijn van Beek, Jurij Aguiar Zdovc, Maddlie Bardol, Marion Dehez   +5 more
wiley   +1 more source

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial [PDF]

, 2016
_Aims/hypothesis:_ Glucagon-like peptide (GLP)-1-based therapies have been suggested to improve hepatic steatosis. We assessed the effects of the GLP-1 receptor agonist liraglutide and the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin on hepatic ...
Bos, I.C. (Indra) van den, Cahen, D.L. (Djuna), Diamant, M. (Michaela), Hoekstra, T. (Trynke), Kramer, M.H.H. (Mark), Muskiet, M.H.A. (Marcel H. A.), Pouwels, P.J.W. (Petra), Smits, M.M. (Mark M.), Tonneijck, L. (Lennart), van Raalte, D.H. (Daniël H.)   +9 more
core   +6 more sources

The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases [PDF]

, 2017
This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care. A “Guidance” document is different from a “Guideline.” Guidelines are developed by a multidisciplinary panel of experts and rate the ...
Brunt, Elizabeth M., Chalasani, Naga, Charlton, Michael, Cusi, Kenneth, Harrison, Stephen A., Lavine, Joel E., Rinella, Mary, Sanyal, Arun J., Younossi, Zobair   +8 more
core   +1 more source

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 9, Page 1215-1235, May 2026.
Peroxisome proliferator‐activated receptor (PPAR) agonists have emerged as important second‐line treatments in primary biliary cholangitis, with profiles influenced by different selectivity for α‐, δ‐ and γ‐isoforms. PPAR‐α and PPAR‐δ agonism improve cholestasis, with inflammation reduced via all isoforms. PPAR‐δ agonism also reduces pruritus.
Jörn M. Schattenberg, Jesus M. Banales, Gideon Hirschfield, Palak Trivedi, Edward E. Cable, Charles A. McWherter, Andrew N. Billin, Daria B. Crittenden, Grant Budas   +8 more
wiley   +1 more source